Stroke prevention in atrial fibrillation

被引:11
作者
Lip, Gregory Y. H. [1 ,2 ,3 ]
Gue, Ying [1 ,2 ]
Zhang, Juqian [1 ,2 ]
Chao, Tze-Fan [4 ,5 ,6 ]
Calkins, Hugh [7 ]
Potpara, Tatjana [8 ,9 ]
机构
[1] Univ Liverpool, Liverpool Ctr Cardiovasc Sci, Liverpool, Merseyside, England
[2] Liverpool Heart & Chest Hosp, Liverpool, Merseyside, England
[3] Aalborg Univ, Dept Clin Med, Aalborg Thrombosis Res Unit, Aalborg, Denmark
[4] Taipei Vet Gen Hosp, Dept Med, Div Cardiol, Taipei, Taiwan
[5] Natl Yang Ming Univ, Inst Clin Med, Taipei, Taiwan
[6] Natl Yang Ming Univ, Cardiovasc Res Ctr, Taipei, Taiwan
[7] Johns Hopkins Med Inst, Dept Cardiol, Baltimore, MD 21205 USA
[8] Univ Belgrade, Sch Med, Belgrade, Serbia
[9] Clin Ctr Serbia, Cardiol Clin, Belgrade, Serbia
关键词
MOBILE HEALTH TECHNOLOGY; BLEEDING RISK-ASSESSMENT; WILLEBRAND-FACTOR LEVELS; ANTITHROMBOTIC THERAPY; ORAL ANTICOAGULANTS; ASIAN PATIENTS; APPENDAGE CLOSURE; ADVERSE EVENTS; STRATIFICATION; OUTCOMES;
D O I
10.1016/j.tcm.2021.10.001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Atrial fibrillation (AF) is the commonest sustained cardiac rhythm disorder associated with an increased risk of stroke and systemic embolic events. The prevention of stroke using oral anticoagulants has been a pivotal component of AF management. The purpose of this review is to summarize recent advances in the treatment and prevention of stroke in AF over the last 5 years. We performed a comprehensive structured literature search using MEDLINE for publications from 11th March 2015 through to 31st December 2020. We focused mainly on primarily published research articles and systematic reviews including updates in different international guidelines. We found that improved awareness and detection of AF and use of clinical risk stratification are central to the identification of patients at risk of stroke who would benefit from oral anticoagulation. The recommendation of non-vitamin K antagonist oral anticoagulants over warfarin in both efficacy and safety perspective is represented in all international guidelines. Beyond stroke prevention, there is a move to more holistic or integrated care management of AF, which has been shown to improve outcomes. We conclude that stroke prevention remains a dominant part of the management of patients with AF. Not all stroke risk factors carry equal weight, and many require additional scrutiny (e.g. severity of CAD, type of diabetes, duration of hypertension). The utilization of clinical risk scores to help decision-making should take into account that these scores are mere simplification tools to aid decision-making and the additional clinical benefit with more complex risk scores and addition of biomarkers is limited. Also, stroke and bleeding risks are dynamic and require regular review. Instead of arbitrarily categorizing patients into (artificial) low, moderate, and high stroke risk strata, anticoagulation should be offered to all patients with AF unless they are low risk with no risk factors for stroke. Stroke prevention is also part of the proactive, integrated care approach to holistic management of patients with AF, which can be simplified in the ABC (Atrial fibrillation Better Care) pathway: `A' Avoid stroke/Anticoagulation; `B' Better symptom management emphasising patient-centred symptom directed decisions on rate or rhythm control strategies; and `C' refers to Cardiovascular risk and comorbidity optimization, including lifestyle changes and attention to patient values and preferences, as well as the psychological morbidity associated with AF. (c) 2021 Elsevier Inc. All rights reserved.
引用
收藏
页码:501 / 510
页数:10
相关论文
共 72 条
[1]   The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation [J].
Andrade, Jason G. ;
Aguilar, Martin ;
Atzema, Clare ;
Bell, Alan ;
Cairns, John A. ;
Cheung, Christopher C. ;
Cox, Jafna L. ;
Dorian, Paul ;
Gladstone, David J. ;
Healey, Jeff S. ;
Khairy, Paul ;
Leblanc, Kori ;
McMurtry, M. Sean ;
Mitchell, L. Brent ;
Nair, Girish M. ;
Nattel, Stanley ;
Parkash, Ratika ;
Pilote, Louise ;
Sandhu, Roopinder K. ;
Sarrazin, Jean-Francois ;
Sharma, Mukul ;
Skanes, Allan C. ;
Talajic, Mario ;
Tsang, Teresa S. M. ;
Verma, Atul ;
Verma, Subodh ;
Whitlock, Richard ;
Wyse, D. George ;
Macle, Laurent .
CANADIAN JOURNAL OF CARDIOLOGY, 2020, 36 (12) :1847-1948
[2]   The Use of Biomarkers in Clinical Management Guidelines: A Critical Appraisal [J].
Asuncion Esteve-Pastor, Maria ;
Roldan, Vanessa ;
Miguel Rivera-Caravaca, Jose ;
Ramirez-Macias, Inmaculada ;
Lip, Gregory Y. H. ;
Marin, Francisco .
THROMBOSIS AND HAEMOSTASIS, 2019, 119 (12) :1901-1919
[3]   Assessing Bleeding Risk in Atrial Fibrillation Patients: Comparing a Bleeding Risk Score Based Only on Modifiable Bleeding Risk Factors against the HAS-BLED Score. The AMADEUS Trial [J].
Asuncion Esteve-Pastor, Maria ;
Miguel Rivera-Caravaca, Jose ;
Shantsila, Alena ;
Roldan, Vanessa ;
Lip, Gregory Y. H. ;
Marin, Francisco .
THROMBOSIS AND HAEMOSTASIS, 2017, 117 (12) :2261-2266
[4]   Long-term bleeding risk prediction in 'real world' patients with atrial fibrillation: Comparison of the HAS-BLED and ABC-Bleeding risk scores The Murcia Atrial Fibrillation Project [J].
Asuncion Esteve-Pastort, Maria ;
Rivera-Caravaca, Jose Miguel ;
Roldan, Vanessa ;
Vicente, Vicente ;
Valdes, Mariano ;
Marin, Francisco ;
Lip, Gregory Y. H. .
THROMBOSIS AND HAEMOSTASIS, 2017, 117 (10) :1848-1858
[5]   GDF15 is elevated in mice following retinal ganglion cell death and in glaucoma patients [J].
Ban, Norimitsu ;
Siegfried, Carla J. ;
Lin, Jonathan B. ;
Shui, Ying-Bo ;
Sein, Julia ;
Pita-Thomas, Wolfgang ;
Sene, Abdoulaye ;
Santeford, Andrea ;
Gordon, Mae ;
Lamb, Rachel ;
Dong, Zhenyu ;
Kelly, Shannon C. ;
Cavalli, Valeria ;
Yoshino, Jun ;
Apte, Rajendra S. .
JCI INSIGHT, 2017, 2 (09)
[6]   Predicting Thromboembolic and Bleeding Event Risk in Patients with Non-Valvular Atrial Fibrillation: A Systematic Review [J].
Borre, Ethan D. ;
Goode, Adam ;
Raitz, Giselle ;
Shah, Bimal ;
Lowenstern, Angela ;
Chatterjee, Ranee ;
Sharan, Lauren ;
LaPointe, Nancy M. Allen ;
Yapa, Roshini ;
Davis, J. Kelly ;
Lallinger, Kathryn ;
Schmidt, Robyn ;
Kosinski, Andrzej ;
Al-Khatib, Sana M. ;
Sanders, Gillian D. .
THROMBOSIS AND HAEMOSTASIS, 2018, 118 (12) :2171-2187
[7]   Performance of the HAS-BLED high bleeding-risk category, compared to ATRIA and HEMORR2HAGES in patients with atrial fibrillation: a systematic review and meta-analysis [J].
Caldeira, Daniel ;
Costa, Joao ;
Fernandes, Ricardo M. ;
Pinto, Fausto J. ;
Ferreira, Joaquim J. .
JOURNAL OF INTERVENTIONAL CARDIAC ELECTROPHYSIOLOGY, 2014, 40 (03) :277-284
[8]   Predicting Adverse Events beyond Stroke and Bleeding with the ABC-Stroke and ABC-Bleeding Scores in Patients with Atrial Fibrillation: The Murcia AF Project [J].
Camelo-Castillo, Anny ;
Miguel Rivera-Caravaca, Jose ;
Marin, Francisco ;
Vicente, Vicente ;
Lip, Gregory Y. H. ;
Roldan, Vanessa .
THROMBOSIS AND HAEMOSTASIS, 2020, 120 (08) :1200-1207
[9]   Off-label dosing of non-vitamin K antagonist oral anticoagulants and clinical outcomes in Asian patients with atrial fibrillation [J].
Chan, Yi-Hsin ;
Chao, Tze-Fan ;
Chen, Shao-Wei ;
Lee, Hsin-Fu ;
Yeh, Yung-Hsin ;
Huang, Ya-Chi ;
Chang, Shang-Hung ;
Kuo, Chi-Tai ;
Lip, Gregory Y. H. ;
Chen, Shih-Ann .
HEART RHYTHM, 2020, 17 (12) :2102-2110
[10]   Incident Co-Morbidities in Patients with Atrial Fibrillation Initially with a CHA2DS2-VASc Score of 0 (Males) or 1 (Females): Implications for Reassessment of Stroke Risk in Initially 'Low-Risk' Patients [J].
Chao, Tze-Fan ;
Liao, Jo-Nan ;
Tuan, Ta-Chuan ;
Lin, Yenn-Jiang ;
Chang, Shih-Lin ;
Lo, Li-Wei ;
Hu, Yu-Feng ;
Chung, Fa-Po ;
Chen, Tzeng-Ji ;
Lip, Gregory Y. H. ;
Chen, Shih-Ann .
THROMBOSIS AND HAEMOSTASIS, 2019, 119 (07) :1162-1170